Photodynamic therapy

Intraocular Drug Delivery

Volumn , Issue , 2006, Pages 129-142

  Kim, Ivana K ^a   Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45849122176     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (53)

1. Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 1900; 39:524-546.
2. von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochenschr 1903; 47:2042-2044.
3. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002; 66:89-106.
4. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53:549-553.
5. van Leengoed HL, Cuomo V, Versteeg AA, van der Veen N, Jori G, Star WM. In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes. Br J Cancer 1994; 69:840-845.
6. Maziere JC, Santus R, Morliere P, et al. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins. J Photochem Photobiol B 1990; 6:61-68.
7. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 1990; 50:483-487.
8. Denekamp J. Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 1984; 23:217-225.
9. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001; 74:656-669.
10. Allison BA, Pritchard PH, Richter AM, Levy JG. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990; 52:501-507.
11. Richter AM, Waterfield E, Jain AK, Sternberg ED, Dolphin D, Levy JG. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990; 52:495-500.
12. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D, Levy JG. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990; 5:231-244.
13. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991; 63:87-93.
14. Richter AM, Yip S, Waterfield E, Logan PM, Slonecker CE, Levy JG. Mouse skin photosensitization with benzoporphyrin derivatives and Photofrin: macroscopic and microscopic evaluation. Photochem Photobiol 1991; 53:281-286.
15. Schmidt-Erfurth U, Bauman W, Gragoudas E, et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 1994; 101:89-99.
16. Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994; 101:1953-1961.
17. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995; 113:810-818.
18. Gomer CJ, Doiron DR, Jester JV, Szirth BC, Murphree AL. Hematoporphyrin derivative photoradiation therapy for the treatment of intraocular tumors: examination of acute normal ocular tissue toxicity. Cancer Res 1983; 43:721-727.
19. Gomer CJ, Doiron DR, White L, et al. Hematoporphyrin derivative photoradiation induced damage to normal and tumor tissue of the pigmented rabbit eye. Curr Eye Res 1984; 3:229-237.
20. Moulton RS, Walsh AW, Miller JW. Response of retinal and choroidal vessels to photodynamic therapy using benzoporphyrin derivative monoacid. Invest Ophthalmol Vis Sci 1993; 34:S1169.
21. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996; 103:427-438.
22. Baumal C, Puliafito CA, Pieroth L. Photodynamic therapy (PDT) of experimental choroidal neovascularization with tin ethyl etiopurprin. Invest Ophthalmol Vis Sci 1996; 37:S122.
23. Waldow SM, Dougherty TJ. Interaction of hyperthermia and photoradiation therapy. Radiat Res 1984; 97:380-385.
24. Husain D, Kramer M, Kenny AG, et al. Effects of photodynamic therapy using verteporfin onexperimental choroidal neovascularization and normal retina and choroid up to 7 weeks after treatment. Invest Ophthalmol Vis Sci 1999; 40:2322-2331.
25. Husain D, Miller JW, Michaud N, Connolly E, Flotte TJ, Gragoudas ES. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996; 114:978-985.
26. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999; 106:1915-1923.
27. Polo L, Reddi E, Garbo GM, Morgan AR, Jori G. The distribution of the tumour photosensitizers Zn(II)-phthalocyanine and Sn(IV)-etiopurpurin among rabbit plasma proteins. Cancer Lett 1992; 66:217-223.
28. Peyman GA, Moshfeghi DM, Moshfeghi A, et al. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers 1997; 28:409-417.
29. Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002; 22:391-405.
30. Arbour JD, Connolly E, Graham K, Gragoudas E, Miller JW. Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin. Invest Ophthalmol Vis Sci 1999; 40(suppl):401.
31. Obana A, Gohto Y, Kaneda K, Nakajima S, Takemura T, Miki T. Selective occlusion of choroidal neovascularization by photodynamic therapy with a water-soluble photosensitizer, ATX-S10. Lasers Surg Med 1999; 24:209-222.
32. Hikichi T, Mori R, Nakajima S, et al. Dynamic observation of selective accumulation of a photosensitizer and its photodynamic effects in rat experimental choroidal neovascularization. Retina 2001; 21:126-131.
33. Obana A, Gohto Y, Kanai M, Nakajima S, Kaneda K, Miki T. Selective photodynamic effects of the new photosensitizer ATX-S10(Na) on choroidal neovascularization in monkeys. Arch Ophthalmol 2000; 118:650-658.
34. Mori K, Yoneya S, Ohta M, et al. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology 1999; 106:1384-1391.
35. Mori K, Yoneya S, Anzail K, et al. Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6. Retina 2001; 21:499-508.
36. Kliman GH, Puliafito CA, Stern D, Borirakchanyavat S, Gregory WA. Phthalocyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Lasers Surg Med 1994; 15:2-10.
37. Asrani S, Zou S, D’Anna S, et al. Feasibility of laser-targeted photoocclusion of the choriocapillary layer in rats. Invest Ophthalmol Vis Sci 1997; 38:2702-2710.
38. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization— verteporfin in photodynamic therapy study group. Am J Ophthalmol 2001; 131:541-560.
39. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results 140 Kim and Miller of an open-label extension of 2 randomized clinical trials—TAP report no. 5. Arch Ophthalmol 2002; 120:1307-1314.
40. Renno RZ, Delori FC, Holzer RA, Gragoudas ES, Miller JW. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2000; 41:3963-3971.
41. Terada Y, Michaud NA, Connolly EJ, et al. Enhanced photodynamic therapy using angiostatin with verteporfin PDT in a laser-injury rat model. Invest Ophthalmol Vis Sci 2003; 44:1749 (E-Abstract).
42. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120:338-346.
43. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005; 123:506-516.
44. Jiang FN, Allison B, Liu D, Levy JG. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems. J Control Release 1992; 19:41-58.
45. Mew D, Lum V, Wat CK, et al. Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res 1985; 45:4380-4386.
46. Mew D, Wat CK, Towers GH, Levy JG. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 1983; 130:1473-1477.
47. Jiang FN, Jiang S, Liu D, Richter A, Levy JG. Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods 1990; 134: 139-149.
48. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19:1525-1533.
49. Renno RZ, Terada Y, Haddadin MJ, et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004; 122:1002-1011.
50. Zacks DN, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest Ophthalmol Vis Sci 2002; 43:2384-2391.
51. Moor AC. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B 2000; 57:1-13.
52. Roberts WG, Liaw LH, Berns MW. In vitro photosensitization II. An electron microscopy study of cellular destruction with mono-L-aspartyl chlorin e6 and photofrin II. Lasers Surg Med 1989; 9:102-108.
53. Rosenkranz AA, Jans DA, Sobolev AS. Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency. Immunol Cell Biol 2000; 78:452-464.